

Supplementary Material

Table S1: Gene variants of preclinical carriers and HOCM patients including mutation type, sex and age of the individuals.

| Gene | Mutation | Type, class | Age | Sex |
|-----------------------------|-------------------------------|---------------------|-----|-----|
| Preclinical Carriers | | | | |
| MYH7 | c.1727A>G p.His576Arg | missense, class 4 | 34 | F |
| MYH7 | c.1207C>T p.Arg403Trp | missense, class 5 | 35 | F |
| MYH7 | c.1816G>A p.Val606Met | missense, class 4/5 | 30 | M |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 58 | F |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 36 | F |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 21 | M |
| MYH7 | c.1207C>T p.Arg403Trp | missense, class 5 | 21 | F |
| MYH7 | c.1207C>T p.Arg403Trp | missense, class 5 | 65 | F |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 44 | F |
| MYH7 | c.5135G>A p.Arg1712Gln | missense, class 4 | 45 | F |
| MYH7 | c.5135G>A p.Arg1712Gln | missense, class 4 | 33 | M |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 18 | F |
| MYH7 | c.4130C>T p.Thr1377Met | missense, class 4 | 31 | F |
| MYBPC3 | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 60 | F |
| MYBPC3 | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 28 | F |
| MYBPC3 | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 30 | F |

| | | | | |
|---------------|-------------------------------|-----------------------|----|---|
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 22 | M |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 34 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 60 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 24 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 56 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 26 | M |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 43 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 31 | F |
| <i>MYBPC3</i> | c.897delG p.Lys301fs | frameshift, class 4/5 | 41 | F |
| <i>TNNT2</i> | c.304C>T p.Arg102Trp | missense, class 5 | 59 | F |
| <i>TNNT2</i> | c.304C>T p.Arg102Trp | missense, class 5 | 58 | F |
| <i>TNNT2</i> | c.856C>T p.Arg286Cys | missense | 48 | F |
| <i>TNNT2</i> | c.430C>T p.Arg144Trp | missense, class 4/5 | 40 | F |
| <i>TNNT2</i> | c.853C>T p.Arg285Cys | missense | 32 | M |
| <i>TNNI3</i> | c.497C>T p.Ser166Phe | missense, class 4/5 | 22 | M |

HOCM patients

| | | | | |
|---------------|-------------------------------|---------------------|----|---|
| <i>MYH7</i> | p.Gln895His | missense | 66 | M |
| <i>MYBPC3</i> | | | 54 | F |
| <i>MYBPC3</i> | c.2373dup p.Trp792ValfsX41 | frameshift, class 5 | 18 | M |
| <i>MYBPC3</i> | c.2827C>T p.Arg943* | frameshift, class 5 | 54 | F |
| <i>TNNT2</i> | c.853C>T | missense | 43 | M |

| | | | | |
|-----------------------------|-------------------------|-----------------------|----|---|
| | p.Arg285Cys | | | |
| TNNT2 | c.304C>T p.Arg102Trp | missense, class 5 | 27 | M |
| TNNT2 | c.856C>T p.Arg286Cys | missense | 53 | M |
| TNNT2 | c.835C>T p.Gln279* | truncation, class 4/5 | 54 | M |
| MYL2 | c.401A>C p.Glu134Ala | missense, class 3/4 | 57 | F |
| Sarcomere mutation negative | | | 64 | M |
| Sarcomere mutation negative | | | 52 | M |
| Sarcomere mutation negative | | | 68 | F |
| Sarcomere mutation negative | | | 46 | M |
| Sarcomere mutation negative | | | 47 | M |

Table S2: Metabolite identifications and functional classes of the top 30 metabolites of all three group-wise comparisons¹.

| Metabolite | Possible identifications | Functional class | p value MEE | padj_BH MEE | p value MVO ₂ | padj_BH MVO ₂ |
|--------------|---|---------------------------------|----------------|----------------|-----------------------------|-----------------------------|
| Metabolite 1 | 19-Hydroxyandrost-4-ene-3,17-dione; 19-Oxotestosterone; 7a-Hydroxyandrost-4-ene-3,17-dione; 11b-Hydroxyandrost-4-ene-3,17-dione; 16a-Hydroxyandrost-4-ene-3,17-dione; 4-Methoxy-17beta-estradiol; 2-Hydroxyestradiol-3-methyl ether | Lipids and lipid-like molecules | | | | |
| Metabolite 2 | p-Ethylacetophenone; Anethole | Benzenoids | | | | |
| Metabolite 3 | Ceramide (d18:1/18:0); Cer(d18:0/18:1(11Z)); Cer(d18:0/18:1(9Z)); N-Stearoylsphingosine | Lipids and lipid-like molecules | 0.0203 | 0.9617 | | |
| Metabolite 4 | Alanyl-Glutamine; Alanyl-Gamma-glutamate; Glutaminyl-Alanine; Gamma-glutamyl-Alanine; N-a-Acetylarginine | Organic acids and derivatives | 0.0226 | 0.9617 | 0.0039 | 0.2924 |
| Metabolite 5 | 11-peroxy-5Z,8Z,12E,14Z-eicosatetraenoate; 9-peroxy-5Z,7E,11Z,14Z-eicosatetraenoate | Lipids and lipid-like molecules | | | 0.0010 | 0.2875 |
| Metabolite 6 | 5-HEPE; Leukotriene A4; 12-HEPE; 14,15-EpETE; 15-HEPE; 15-KETE; 17,18-EpETE; 5-KETE; 11R-HEPE; 18R-HEPE; 9-HEPE | Lipids and lipid-like molecules | | | 0.0010 | 0.2875 |

| | | |
|---------------|--|---------------------------------|
| Metabolite 7 | Prostaglandin E3; Prostaglandin D3; 15-Keto-prostaglandin E2; Resolvin E1; 12-Oxo-20-hydroxy-leukotriene B4; 15-Epi-lipoxin B5; 15-Oxo-lipoxin A4; 20-oxo-leukotriene B4; PGH3; 5,12,18R-TriHEPE; 8-iso-15-keto-PGE2 | Lipids and lipid-like molecules |
| Metabolite 8 | 4-Hydroxy-5-(3',5'-dihydroxyphenyl)-valeric acid-O-methyl-O-glucuronide; 4-Hydroxy-5-(3',4'-dihydroxyphenyl)-valeric acid-O-methyl-O-glucuronide | Organic oxygen compounds |
| Metabolite 9 | Tryptophyl-Serine; Serinyl-Tryptophan | Organic acids and derivatives |
| Metabolite 10 | O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->4)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol; O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-1,5-anhydro-2-deoxy-D-arabino-Hex-1-enitol | Organic oxygen compounds |
| Metabolite 11 | Alanyl-Leucine; Isoleucyl-Alanine; Leucyl-Alanine; Alanyl-Isoleucine | Organic acids and derivatives |
| Metabolite 12 | Tyrosyl-Glutamate; Glutamyl-Tyrosine | Organic acids and derivatives |
| Metabolite 13 | Glutamyl-Alanine; Alanyl-Glutamate | Organic acids and derivatives |
| Metabolite 14 | sn-glycero-3-Phosphoethanolamine; Glycerylphosphorylethanolamine | Lipids and lipid-like molecules |

| | | | | | |
|---------------|--|---------------------------------|---------------|--------|--|
| Metabolite 15 | S-Acetyl-dihydrolipoamide; S-Acetyl-dihydrolipoamide-E | Lipids and lipid-like molecules | | | |
| Metabolite 16 | Medroxyprogesterone; 17-HDoHE; 19(20)-EpDPE; 16(17)-EpDPE; 10-HDoHE; 11-HDoHE; 16-HDoHE; 20-HDoHE; 4-HDoHE; 7-HDoHE; 8-HDoHE; 4-Hydroxy-all-trans-retinyl acetate | Lipids and lipid-like molecules | 0.0009 | 0.2875 | |
| Metabolite 17 | Aspartyl-Glutamate; Glutamyl-Aspartate | Organic acids and derivatives | | | |
| Metabolite 18 | MG(0:0/20:3(5Z,8Z,11Z)/0:0); MG(0:0/20:3(8Z,11Z,14Z)/0:0); MG(20:3(11Z,14Z,17Z)/0:0/0:0); MG(20:3(5Z,8Z,11Z)/0:0/0:0); MG(20:3(8Z,11Z,14Z)/0:0/0:0); MG(0:0/20:3(11Z,14Z,17Z)/0:0) | Lipids and lipid-like molecules | 0.0012 | 0.9617 | |
| Metabolite 19 | Hydroxyprolyl-Valine; Valyl-Hydroxyproline | Organic acids and derivatives | | | |
| Metabolite 20 | Asparaginyl-Tryptophan; Histidinyl-Tyrosine; Tryptophyl-Asparagine; Tyrosyl-Histidine | Organic acids and derivatives | | | |
| Metabolite 21 | Asymmetric dimethylarginine; Symmetric dimethylarginine | Organic acids and derivatives | 0.0045 | 0.2924 | |
| Metabolite 22 | Estriol; 2-Hydroxyestradiol; 16b-Hydroxyestradiol; 17-Epiestriol; 16,17-Epiestriol; 4-Hydroxyestradiol; 2-Polyprenyl- | Lipids and lipid-like molecules | 0.0014 | 0.2875 | |

| | | | | | |
|---------------|--|---------------------------------|---------|--------|--|
| | 3-methyl-6-methoxy-1,4-benzoquinone; 4-hydroxystradiol | | | | |
| Metabolite 23 | Alpha-CEHC; Monoethylhexyl phthalic acid | Organoheterocyclic compounds | <0.0001 | 0.1720 | |
| Metabolite 24 | Asparaginyl-Lysine; Lysyl-Asparagine | Organic acids and derivatives | | | |
| Metabolite 25 | Tetracosahexaenoic acid; Tetracosahexaenoic acid, n-3 | Lipids and lipid-like molecules | 0.0043 | 0.2924 | |
| Metabolite 26 | 3'-Hydroxy-e,e-caroten-3-one; 3-Hydroxy-b,e-caroten-3'-one | Lipids and lipid-like molecules | 0.0076 | 0.3950 | |
| Metabolite 27 | 15-Keto-13,14-dihydroprostaglandin A2; Prostaglandin J2; Prostaglandin A2; 12-Keto-leukotriene B4; Prostaglandin B2; Delta-12-Prostaglandin J2; Leukotriene B5; 5-Oxo-6-trans-leukotriene B4; 7'-Carboxy-gamma-chromanol; 15d PGD2; bicyclo-PGE2; Prostaglandin-c2 | Lipids and lipid-like molecules | 0.0190 | 0.5463 | |
| Metabolite 28 | DG(16:0/15:0/0:0); DG(15:0/0:0/16:0); DG(15:0/16:0/0:0) | Lipids and lipid-like molecules | | | |
| Metabolite 29 | Lysyl-Glutamine; Lysyl-Gamma-glutamate; Gamma-glutamyl-Lysine; Glutaminyl-Lysine | Organic acids and derivatives | 0.0107 | 0.9617 | |
| Metabolite 30 | DG(15:0/14:0/0:0); DG(14:0/0:0/15:0); DG(14:0/15:0/0:0) | Lipids and lipid-like molecules | 0.0117 | 0.4829 | |

| | | | | |
|---------------|--|---------------------------------|---------------|--------|
| Metabolite 31 | Cysteinyl-Leucine; Isoleucyl-Cysteine; Leucyl-Cysteine; Cysteinyl-Isoleucine | Organic acids and derivatives | | |
| Metabolite 32 | Tyrosyl-Glutamine; Tyrosyl-Gamma-glutamate; gln-tyr; Glutaminyl-Tyrosine | Organic acids and derivatives | | |
| Metabolite 33 | N-Acetyl-a-neurameric acid; N-Acetylneurameric acid | Organic oxygen compounds | | |
| Metabolite 34 | MG(20:5(5Z,8Z,11Z,14Z,17Z)/0:0/0:0); 9'-Carboxy-gamma-chromanol; MG(0:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0) | Lipids and lipid-like molecules | 0.0110 | 0.9617 |
| Metabolite 35 | 5-(3',4',5'-trihydroxyphenyl)-gamma-valerolactone-O-methyl-5'-O-glucuronide; 5-(3',4',5'-trihydroxyphenyl)-gamma-valerolactone-O-methyl-4'-O-glucuronide | Organic oxygen compounds | 0.0200 | 0.9617 |
| Metabolite 36 | Tyrosyl-Cysteine; Cysteinyl-Tyrosine | Organic acids and derivatives | | |
| Metabolite 37 | 5-Hydroxyindoleacetaldehyde; Indoleacetic acid | | | |
| Metabolite 38 | Histidinyl-Threonine; Threoninyl-Histidine; 2-(3-Carboxy-3-aminopropyl)-L-histidine | Organic acids and derivatives | | |
| Metabolite 39 | DG(14:1(9Z)/20:0/0:0); DG(16:0/18:1(11Z)/0:0); DG(16:0/18:1(9Z)/0:0); DG(16:1(9Z)/18:0/0:0); DG(18:0/16:1(9Z)/0:0); DG(18:1(11Z)/16:0/0:0); DG(18:1(9Z)/16:0/0:0); DG(20:0/14:1(9Z)/0:0); DG(20:1(11Z)/14:0/0:0); DG(14:0/0:0/20:1n9); | Lipids and lipid-like molecules | | |

| | | | | |
|--|---|---------------------------------|---------------|--------|
| | DG(16:0/0:0/18:1n7); DG(16:0/0:0/18:1n9); DG(18:0/0:0/16:1n7); DG(20:0/0:0/14:1n5); DG(14:0/20:1(11Z)/0:0) | | | |
| Metabolite 40 | Chenodeoxycholic acid 3-sulfate; Ursodeoxycholic acid 3-sulfate; Chenodeoxycholic acid sulfate | Lipids and lipid-like molecules | | |
| Metabolite 41 | MG(0:0/18:3(6Z,9Z,12Z)/0:0); MG(0:0/18:3(9Z,12Z,15Z)/0:0); MG(18:3(6Z,9Z,12Z)/0:0/0:0); MG(18:3(9Z,12Z,15Z)/0:0/0:0) | Lipids and lipid-like molecules | 0.0012 | 0.9617 |
| 1,3,5-Trimethoxybenzene | | Benzenoids | | |
| 2-Pyrrolidinone | | Organoheterocyclic compounds | | |
| 3-Polypropenyl-4,5-dihydroxybenzoate | | Benzenoids | 0.0042 | 0.2924 |
| 3,4-Methylenesebacic acid | | Lipids and lipid-like molecules | | |
| 5-(methylthio)-2,3-Dioxopentyl phosphate | | Organic acids and derivatives | 0.0013 | 0.9617 |
| 5b-Cyprinol sulfate | | Lipids and lipid-like molecules | | |
| 6-Carboxy-5,6,7,8-tetrahydropterin | | Organoheterocyclic compounds | | |

| | | | |
|--|---------------------------------|---------------|--------|
| 6-Dimethylaminopurine | Organoheterocyclic compounds | | |
| 7-Hydroxy-6-methyl-8-ribityl lumazine | Organoheterocyclic compounds | | |
| 7a,12a-Dihydroxy-3-oxo-4-cholenoic acid | Lipids and lipid-like molecules | 0.0003 | 0.1957 |
| 8-[(Aminomethyl)sulfanyl]-6-sulfanyloctanoic acid | Lipids and lipid-like molecules | | |
| 9'-Carboxy-gamma-tocotrienol | Lipids and lipid-like molecules | 0.0486 | 0.6320 |
| 11beta,20-Dihydroxy-3-oxopregn-4-en-21-oic acid | Lipids and lipid-like molecules | 0.0086 | 0.4078 |
| 13'-Hydroxy-alpha-tocotrienol | Lipids and lipid-like molecules | | |
| 19,20-DiHDPA | Lipids and lipid-like molecules | | |
| Cinnavalininate | Organoheterocyclic compounds | | |
| Cytidine 2',3'-cyclic phosphate | Organic acids and derivatives | | |

| | | | |
|-------------------------------|--|---------------|--------|
| dADP | Nucleosides, nucleotides and analogues | 0.0459 | 0.9617 |
| Dimethyl sulfone | Organosulfur compounds | | |
| Dityrosine | Organic acids and derivatives | 0.0208 | 0.9617 |
| Epinephrine glucuronide | Organic oxygen compounds | | |
| Equol | Phenylpropanoids and polyketides | | |
| Gamma | Organic acids and derivatives | 0.0447 | 0.9617 |
| Glutamylglutamic acid | | | |
| Glutaryl carnitine | Lipids and lipid-like molecules | | |
| Glycineamideribotide | Nucleosides, nucleotides and analogues | | |
| Heptyl ketone | Organic oxygen compounds | | |
| Indoleacetyl glutamine | Organic acids and derivatives | 0.0469 | 0.6225 |
| Mesoporphyrin IX | Organoheterocyclic compounds | | |
| N-Acetylaspartylglutamic acid | Organic acids and derivatives | 0.0251 | 0.5533 |

| | | | | | |
|-----------------------------|--|---------------|--------|---------------|--------|
| N-Acetylhistamine | Organic acids and derivatives | | | | |
| Palmitoyl glucuronide | Lipids and lipid-like molecules | 0.0239 | 0.9617 | 0.5533 | |
| Pentadecanoylglycine | Organic acids and derivatives | 0.0197 | 0.9617 | 0.5463 | |
| Pentaporphyrin I | Organoheterocyclic compounds | 0.0379 | 0.9617 | | |
| Perillic acid | Lipids and lipid-like molecules | | | | |
| Phosphocreatinine | Organic acids and derivatives | | | | |
| Ribose-1-arsenate | Organic oxygen compounds | | | | |
| SAICAR | Nucleosides, nucleotides and analogues | 0.0126 | 0.9617 | | |
| Stearic acid | Lipids and lipid-like molecules | | | | |
| Stigmastanol | Lipids and lipid-like molecules | | | | |
| Tetracosanoic acid | Lipids and lipid-like molecules | 0.0119 | 0.9617 | 0.0318 | 0.5549 |
| Vanilloylglycine | Benzenoids | 0.0386 | 0.9617 | | |

¹Metabolites in bold are significant in 2 comparisons. P value is given for metabolites that correlate significantly with myocardial external efficiency (MEE) or myocardial oxygen consumption (MVO₂), together with the adjusted p value for multiple testing.

Table S3: Metabolite-Protein links identified with MetaBridge.

| Carrier vs Ctrl | Carrier vs HOCM | HOCM vs Ctrl |
|-----------------|-----------------|--------------|
| LTA4H | DDAH1 | ALDH9A1 |
| LYPLA1 | | ALDH3A2 |
| | | ALDH7A1 |
| | | GART |





Figure S1: Overview of gene variants in this study. (A) shows the protein domains in which the gene variants are located. Image with permission granted by Vasco Sequeira. (B) indicates the location of the gene variants in the structural context. Image adapted from Sequeira et al. Circ Res 2013 with permission Circ Res.

Figure S2





Figure S2: Multivariate modelling. (A) Partial least square-discriminant analysis plots (PLS-DA) for the three group-wise comparisons Carrier vs Ctrl, Carrier vs HOCM and HOCM vs Ctrl. (B) ROC curves of the three group-wise comparisons presenting the performance of the metabolomics data in distinguishing the groups. (C) Top 30 most predictive metabolites with corresponding $-\log_{10}(p)$ -values.


Carrier vs Ctrl

Organic acids and derivatives


Amino acids, peptides and analogues




Metabolite 4
Alanyl-Glutamine
Alanyl-Gamma-glutamate
Glutamyl-Alanine
Gamma-glutamyl-Alanine
N-a-Acetylarginine




Metabolite 9
Tryptophyl-Serine
Serinyl-Tryptophan






Metabolite 11
Alanyl-Leucine
Isoleucyl-Alanine
Leucyl-Alanine
Alanyl-Isoleucine




Metabolite 12
Tyrosyl-Glutamate
Glutamyl-Tyrosine




Metabolite 13
Glutamyl-Alanine
Alanyl-Glutamate



Phosphate esters




Carboxylic acid derivatives




Carrier vs Ctrl

Lipids and lipid-like molecules



Fatty acids and conjugates




Metabolite 5
11-peroxy-5Z,8Z,12E,14Z-eicosatetraenoate
9-peroxy-5Z,7E,11Z,14Z-eicosatetraenoate



Metabolite 6
5-HEPE
Leukotriene A4
12-HEPE
14,15-EpETE
15-HEPE
15-KETE
17,18-EpETE
5-KETE
11R-HEPE
18R-HEPE
9-HEPE




Ceramides




Metabolite 3
Ceramide (d18:1/18:0)
Cer(d18:0/18:1(11Z))
Cer(d18:0/18:1(9Z))
N-Stearoylsphingosine

Eicosanoids




Metabolite 7
Prostaglandin E3
Prostaglandin D3
15-Keto-prostaglandin E2
Resolvin E1
12-Oxo-20-hydroxy-leukotriene B4
15-Epi-lipoxin B5
15-Oxo-lipoxin A4
20-oxo-leukotriene B4
PGH3
5,12,18R-TriHEPE
8-iso-15-keto-PGE2

Monoterpenoids




Glycerophosphoethanolamines



Metabolite 14
sn-glycero-3-Phosphoethanolamine
Glycerylphosphorylethanolamine

Androstane steroids



Metabolite 1
19-Hydroxyandrost-4-ene-3,17-dione
19-Oxotestosterone
7a-Hydroxyandrost-4-ene-3,17-dione
11b-Hydroxyandrost-4-ene-3,17-dione
16a-Hydroxyandrost-4-ene-3,17-dione
4-Methoxy-17beta-estradiol
2-Hydroxyestradiol-3-methyl ether

Carrier vs Ctrl





Figure S3: Bar graphs with individual data points of the top 30 most important metabolites in distinguishing the Carrier vs Ctrl group. Data from the third group is included in all graphs.

Carrier vs HOCM


Organic acids and derivatives

Amino acids, peptides and analogues




Organic oxygen compounds

Carbonyl compounds




Carbohydrates and carbohydrate conjugates



Phenylpropanoids and polyketides


Isoflavans




Carrier vs HOCM

Lipids and lipid-like molecules


Fatty acids and conjugates




Metabolite 5
11-peroxy-5Z,8Z,12E,14Z-eicosatetraenoate
9-peroxy-5Z,7E,11Z,14Z-eicosatetraenoate



Metabolite 16
Medroxyprogesterone
17-HDoHE
19(20)-EpDPE
16(17)-EpDPE
10-HDoHE
11-HDoHE
16-HDoHE
20-HDoHE
4-HDoHE
7-HDoHE
8-HDoHE
4-Hydroxy-all-trans-retinyl acetate




Lineolic acids and derivatives




Metabolite 18
MG(0:0/18:3(6Z,9Z,12Z)/0:0)
MG(0:0/18:3(9Z,12Z,15Z)/0:0)
MG(18:3(6Z,9Z,12Z)/0:0/0:0)
MG(18:3(9Z,12Z,15Z)/0:0/0:0)

Estrane steroids




Metabolite 22
Estriol
2-Hydroxyestradiol
16 β -Hydroxyestradiol
17-Epiestriol
16,17-Epiestriol
4-Hydroxyestradiol
2-Polypropenyl-3-methyl-6-methoxy-1,4-benzoquinone
4-hydroxyestradiol


Cholestane steroids



Oxosteroids




Metabolite 25




Metabolite 25
Tetracosahexaenoic acid
Tetracosahexaenoic acid, n-3

Eicosanoids



Metabolite 27
15-Keto-13,14-dihydroprostaglandin A2
Prostaglandin J2
Prostaglandin A2
12-Keto-leukotriene B4
Prostaglandin B2
Delta-12-Prostaglandin J2
Leukotriene B5
5-Oxo-6-trans-leukotriene B4
7'-Carboxy-gamma-chromanol
15d PGD2
bicyclo-PGE2
Prostaglandin-c2

Tetraterpenoids




Metabolite 26
3-Hydroxy-e,e-caroten-3-one
3-Hydroxy-b,e-caroten-3'-one


Carrier vs HOCM

Lipids and lipid-like molecules

Fatty amides




Quinone and hydroquinone lipids




Bzenenoids


Benzoic acids and derivatives



Fatty acyl glycosides




Fatty acid esters




Organoheterocyclic compounds


Porphyrins



Pyrrolidones



1-benzopyrans



Pteridines and derivatives





Figure S4: Bar graphs with individual data points of the top 30 most important metabolites in distinguishing the Carrier vs HOCM group. Data from the third group is included in all graphs.


HOCM vs Ctrl

Organic acids and derivatives


Amino acids, peptides and analogues




Metabolite 29
Lysyl-Glutamine
Lysyl-Gamma-glutamate
Gamma-glutamyl-Lysine
Glutaminyl-Lysine




Metabolite 31
Cysteinyl-Leucine
Isoleucyl-Cysteine
Leucyl-Cysteine
Cysteinyl-Isoleucine





Metabolite 32
Tyrosyl-Glutamine
Tyrosyl-Gamma-glutamate
gln-tyr
Glutaminyl-Tyrosine




Metabolite 36
Tyrosyl-Cysteine
Cysteinyl-Tyrosine



Metabolite 38
Histidinyl-Threonine
Threoninyl-Histidine
2-(3-Carboxy-3-aminopropyl)-L-histidine




Gamma Glutamylglutamic acid




Nucleosides, nucleotides and analogues


Purine deoxyribonucleotides



Glycinamide ribonucleotides




1-ribosyl-imidazolecarboxamides




HOCM vs Ctrl

Lipids and lipid-like molecules


Fatty acids and conjugates




Stigmastanes and derivatives




Oxosteroids




Bile acids, alcohols and derivatives



Metabolite 40
Chenodeoxycholic acid 3-sulfate
Ursodeoxycholic acid 3-sulfate
Chenodeoxycholic acid sulfate




Lineolic acids and derivatives




Metabolite 41
MG(0:0/18:3(6Z,9Z,12Z)/0:0)
MG(0:0/18:3(9Z,12Z,15Z)/0:0)
MG(18:3(6Z,9Z,12Z)/0:0/0:0)
MG(18:3(9Z,12Z,15Z)/0:0/0:0)

Ceramides




Metabolite 3
Ceramide (d18:1/18:0)
Cer(d18:0/18:1(11Z))
Cer(d18:0/18:1(9Z))
N-Stearoylceramide

Monoradylglycerols




Metabolite 34
MG(20:5(5Z,8Z,11Z,14Z,17Z)/0:0/0:0)
9'-Carboxy-gamma-chromanol
MG(0:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)

Quinone and hydroquinone lipids




Monoterpenoids



HOCM vs Ctrl


Lipids and lipid-like molecules

Diradylglycerols




Organic oxygen compounds

Carbohydrates and carbohydrate conjugates




Benzoids

Anisoles



Organoheterocyclic compounds

Pterins and derivatives



Hydroxyindoles




Figure S5: Bar graphs with individual data points of the top 30 most important metabolites in distinguishing the HOCM vs Ctrl group. Data from the third group is included in all graphs.